CCRM Australia accelerates the commercialisation of regenerative medicine therapies and related technologies. We do this by providing specialist expertise, funding opportunities and connections between industry, clinicians, researchers, and other key stakeholders.

CCRM Australia 2020 Impact Report

View the CCRM Australia 2020 Impact Report as a PDF.

CCRM Australia National Regenerative Medicine SuperPitch

Call for Expressions of Interest

The Centre for Commercialization of Regenerative Medicine (CCRM) Australia again partners with local and international venture capital firms to hold a second National Regenerative Medicine SuperPitch. The SuperPitch offers expertise and investment funding for translation and commercialisation of Australian projects related to regenerative medicine.

Regenerative medicine includes technologies and therapies that regenerate or replace injured, diseased, or defective cells, tissues, or organs to restore or establish function and structure. Submissions may relate to cell therapies, gene therapies, combination therapies, gene editing tools, enabling technologies such as vector production, automated analytical assays, biosensors, novel media, and other projects related to regenerative medicine in a wide range of therapeutic area.   

The National Regenerative Medicine SuperPitch provides an opportunity for companies and researchers to showcase their technologies or ideas. Expert feedback, commercialisation support from CCRM Australia and (for suitable projects) further development funding will be made available. The participation of partners with expertise in various specialties and lifecycle stages empowers the SuperPitch to streamline progress from proof of concept through to clinical trials.

Shortlisted applicants will be invited to provide a thirty-minute presentation, which must include objective data on their technologies to a panel of regenerative medicine, venture capital and commercialisation experts from the consortia. A discussion period will extend the total presentation period to 45 minutes.

The second CCRM Australia National Regenerative Medicine SuperPitch will be held online on the morning of the 4th of December 2020. The video conferencing application Zoom will be used for all participants.

Key Dates:

Applications via expression of interest close 5 pm AEDT Friday, 23rd October 2020

Shortlisted applicants will be informed during the week commencing 9th November 2020

SuperPitch Event: Friday, 4th December 2020

Please refer to the FAQ’s, or contact Dr Jack Lambshead at for more information.

BioBusiness Insights – Opportunities in Regenerative Medicine

CCRM Australia, in collaboration with BioMelbourne Network, will be delivering a series of stand-alone webinars focusing on the regenerative medicine industry. Comprising presentations from both local and international speakers, the seminars aim to deliver insights and knowledge on themes that drive business success both locally and internationally, uniting the industry across research, translation and commercialisation, and progressing trade and export activities with key global markets.

Supporting local enterprises with global ambitions, the seminars will provide an important opportunity to drive international connectivity and showcase Victoria’s capabilities to a wide-reaching audience across the APAC region.

Through virtual participation, attendees will gain a deeper understanding of the local and global markets, the opportunities and challenges that exist for regenerative medicine businesses across the APAC region, and an insight into the successes and failures of those who have navigated the complex pathway to market before us.

This series aims to inform a broad yet focused audience of professionals with strategic intent or general interest in the thriving regenerative medicine sector. BioMelbourne Network and CCRM Australia encourage business executives, established and emerging scientists, entrepreneurs, managers and decision makers, and government representatives across the APAC region to attend.

The seminars will be delivered over a 4-month period, with one keynote speaker presenting per session. Attendees will have the opportunity to engage with the speakers through an online Q&A platform and have their questions discussed throughout the session.

The event program is designed with flexibility in mind. Attendees can opt to register for the complete series, or a select few, pending their specific interests.

Click here to book

CCRM Australia 2019 Annual Report

CCRM Australia Prospectus

CCRM Australia Prospectus 2019 cover page

View the CCRM Australia Prospectus 2019 as a PDF.

CCRM Australia 2018 Annual Report

The last 12 months have seen significant progress with CCRM Australia. With the endorsement of the 5-year strategic plan by the CCRM Australia Council and its subsequent approval by key stakeholders, CCRM Australia have been able to address many critical operational objectives and achieved several key milestones.


What is CCRM?

Australia’s leading regenerative medicine researchers have come together in a coordinated, collaborative fashion to support the creation of CCRM Australia.

CCRM Australia is a not for profit established to address bottlenecks in the translation and commercialisation of RM discoveries in Australia.

CCRM Australia is modelled on the highly successful CCRM in Canada and is legally separate to CCRM.

As a member of the Global CCRM network, CCRM Australia is a partner to a leading edge industry consortium. CCRM Australia is taking RM from bench to bedside by treating and potentially curing some of the most devastating and costly diseases in the world today.

What is Canada’s Centre for Commercialization of Regenerative Medicine (CCRM)?

Since its inception in 2011, CCRM has become globally recognised as a translation centre and has become a leading global commercial hub for regenerative medicine and cell therapy. In partnership with top research institutions in Canada and abroad, and with a consortium of global industry leaders, CCRM has established a track record of developing and commercialising innovative technologies that tackle significant bottlenecks in the industry.

Examples of this include:

  • evaluation of novel biomaterials to enable cell product shipping,
  • process optimisation on a cell therapy resulting in a 60% reduction in cost of goods,
  • advancement of two novel drug screening platforms aimed at the direct measurement of contraction forces by contractile cells,
  • co-development of image analysis software to enable analysis in a novel drug screening platform,
  • development of novel cryopreservation approaches for specialised cells, and
  • development of scalable expansion protocols for pluripotent stem cells.

CCRM has developed and implemented an efficient model for technology transfer that includes:

  • in-licensing of technologies,
  • value adding development either alone or in partnership with companies or academics,
  • out-licensing of technologies/ processes to existing companies, and
  • the bundling of technologies to create spin-out companies.

CCRM has approached ARMI at the Monash University Clayton Campus to establish an Australian ‘hub’ modelled along the CCRM operational model. This hub will be developed in parallel with other emerging hubs in Israel, Japan, Europe and Singapore.

The benefits of the introduction of the CCRM model to Australia include:

  • immediate access to a demonstrated commercialisation model and sector specific expertise developed by CCRM to be utilised for the benefit of local regenerative medicine discoveries
  • regenerative medicine product development, licensing and regulatory expertise
  • membership of a large consortium that includes the major companies working in regenerative medicine
  • access to a consortium of world-leading regenerative medicine companies providing business skills and leadership, funds for product development, and receptor capacity for technologies and products
  • strong link to industry trends and needs through the industry consortium